Cargando…

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections

(1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem monotherapy and microbiological outcome in a case series of urological patients with documented Gram-negative infections. (2...

Descripción completa

Detalles Bibliográficos
Autores principales: Berrino, Pasquale Maria, Gatti, Milo, Rinaldi, Matteo, Brunocilla, Eugenio, Viale, Pierluigi, Pea, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525318/
https://www.ncbi.nlm.nih.gov/pubmed/37760685
http://dx.doi.org/10.3390/antibiotics12091388
_version_ 1785110755289333760
author Berrino, Pasquale Maria
Gatti, Milo
Rinaldi, Matteo
Brunocilla, Eugenio
Viale, Pierluigi
Pea, Federico
author_facet Berrino, Pasquale Maria
Gatti, Milo
Rinaldi, Matteo
Brunocilla, Eugenio
Viale, Pierluigi
Pea, Federico
author_sort Berrino, Pasquale Maria
collection PubMed
description (1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem monotherapy and microbiological outcome in a case series of urological patients with documented Gram-negative infections. (2) Methods: Patients admitted to the urology ward who were treated with CI piperacillin–tazobactam or meropenem monotherapy for documented Gram-negative infections and underwent real-time therapeutic drug monitoring (TDM)-guided expert clinical pharmacological advice (ECPA) program from June 2021 to May 2023 were retrospectively retrieved. Average steady-state (C(ss)) piperacillin–tazobactam and meropenem concentrations were determined, and the free fractions (fC(ss)) were calculated. Optimal PK/PD target attainments were defined as an fC(ss)/MIC ratio >4 for CI meropenem and an fC(ss)/MIC ratio of piperacillin >4 coupled with an fC(ss)/C(T) ratio for tazobactam >1 for piperacillin–tazobactam (joint PK/PD target). The relationship between beta-lactam PK/PD targets and microbiological outcome was explored. (3) Results: Sixteen urologic patients with documented Gram-negative infections (62.5% complicated urinary tract infections (cUTI)) had 30 TDM-guided ECPAs. At first TDM assessment, beta-lactam dosing adjustments were recommended in 11 out of 16 cases (68.75%, of which 62.5% decreases and 6.25% increases). Overall, beta-lactam dosing adjustments were recommended in 14 out of 30 ECPAs (46.6%). Beta-lactam PK/PD target attainments were optimal in 100.0% of cases. Microbiological failure occurred in two patients, both developing beta-lactam resistance. (4) Conclusion: A TDM-guided ECPA program may allow for optimizing beta-lactam treatment in urologic patients with documented Gram-negative infections, ensuring microbiological eradication in most cases.
format Online
Article
Text
id pubmed-10525318
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105253182023-09-28 Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections Berrino, Pasquale Maria Gatti, Milo Rinaldi, Matteo Brunocilla, Eugenio Viale, Pierluigi Pea, Federico Antibiotics (Basel) Article (1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem monotherapy and microbiological outcome in a case series of urological patients with documented Gram-negative infections. (2) Methods: Patients admitted to the urology ward who were treated with CI piperacillin–tazobactam or meropenem monotherapy for documented Gram-negative infections and underwent real-time therapeutic drug monitoring (TDM)-guided expert clinical pharmacological advice (ECPA) program from June 2021 to May 2023 were retrospectively retrieved. Average steady-state (C(ss)) piperacillin–tazobactam and meropenem concentrations were determined, and the free fractions (fC(ss)) were calculated. Optimal PK/PD target attainments were defined as an fC(ss)/MIC ratio >4 for CI meropenem and an fC(ss)/MIC ratio of piperacillin >4 coupled with an fC(ss)/C(T) ratio for tazobactam >1 for piperacillin–tazobactam (joint PK/PD target). The relationship between beta-lactam PK/PD targets and microbiological outcome was explored. (3) Results: Sixteen urologic patients with documented Gram-negative infections (62.5% complicated urinary tract infections (cUTI)) had 30 TDM-guided ECPAs. At first TDM assessment, beta-lactam dosing adjustments were recommended in 11 out of 16 cases (68.75%, of which 62.5% decreases and 6.25% increases). Overall, beta-lactam dosing adjustments were recommended in 14 out of 30 ECPAs (46.6%). Beta-lactam PK/PD target attainments were optimal in 100.0% of cases. Microbiological failure occurred in two patients, both developing beta-lactam resistance. (4) Conclusion: A TDM-guided ECPA program may allow for optimizing beta-lactam treatment in urologic patients with documented Gram-negative infections, ensuring microbiological eradication in most cases. MDPI 2023-08-31 /pmc/articles/PMC10525318/ /pubmed/37760685 http://dx.doi.org/10.3390/antibiotics12091388 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Berrino, Pasquale Maria
Gatti, Milo
Rinaldi, Matteo
Brunocilla, Eugenio
Viale, Pierluigi
Pea, Federico
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
title Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
title_full Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
title_fullStr Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
title_full_unstemmed Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
title_short Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
title_sort pharmacokinetic/pharmacodynamic target attainment of continuous infusion piperacillin–tazobactam or meropenem and microbiological outcome among urologic patients with documented gram-negative infections
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525318/
https://www.ncbi.nlm.nih.gov/pubmed/37760685
http://dx.doi.org/10.3390/antibiotics12091388
work_keys_str_mv AT berrinopasqualemaria pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections
AT gattimilo pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections
AT rinaldimatteo pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections
AT brunocillaeugenio pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections
AT vialepierluigi pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections
AT peafederico pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections